Lv3
240 积分 2025-02-08 加入
Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA
2天前
已完结
Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species
2天前
已完结
International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions
24天前
已完结
Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors
24天前
已完结
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
1个月前
已完结
Morphine and hydromorphone pharmacokinetics in human volunteers: population-based modelling of interindividual and opioid-related variability
2个月前
已完结
Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors
2个月前
已完结
Once‐ Versus Twice‐Daily Tacrolimus Therapy: Does Improved Adherence Lead to Better Efficacy?—A Pharmacokinetic Perspective
3个月前
已完结
Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications
7个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7个月前
已完结
皖公网安备34019202002308
